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recurred and previously radiated digestive tumors. This 
treatment offers adequate locoregional control with 
acceptable range of complications. 
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Purpose or Objective: To study normal skin acute toxicity in 
Non-Melanoma Skin Cancer (NMSC) patients treated with High 
Dose Rate (HDR) Plesiotherapy and very high viscosity 
addition silicone (VHVAS) rubber custom-made molds. VHVAS 
rubber features excellent mechanical and physical properties 
which benefit the stability and reproducibility of the implant. 
On the other hand, the high electron density relative to 
water of these materials will increase the scatter production, 
which may be relevant at the mold-skin interface. 
 
Material and Methods: Our standard applicators are 
polymerized VHVAS molds with catheters embedded. This 
VHVAS model features 99.5% recovery factor after 
compression and maximum 0.20% linear dimensional 
variations. Dosimetric properties of this VHVAS have been 
characterized by our Group elsewhere. Silicone attenuation 
relative to water is <5% up to 3 mm thickness. Maximum 
scatter relative to water measured at the mold interface is 
<14%. Treatment is delivered with a Ir-192 based VARIAN MS 
Gammamed+ HDR unit. All treatments are 3D simulated. A 
sample of 15 Patients with 21 lesions (8 basal cell 
carcinomas, 13 squamous cell carcinomas) representing all 
treated locations were considered. Average age is 83.1 years 
[96-58], 47% without any concomitant diseases and life 
expectancy >5 years. Median lesion area is 5.4 cm2 [1.0-
46.6], treatment depth is 4.0 mm [2-15] and microscopic 
disease margin is 4 mm [2-5]. Standard fractionation is 5.5 
Gy/fr, 10-12 fr, twice a week. Acute toxicity was 
retrospectively assessed following the RTOG criteria. 
 
Results: DVH analysis showed high dose areas having: 
D1cc=8.5 Gy/fr [5.4-14.4], D0.5cc= 9.0 Gy/fr [5.4-16.3], 
D0.1cc= 10.3 Gy/fr [6.2-22.9]. All patients presented 
radiodermatitis 1 month after treatment (G2: 89%, G3: 11%). 
32% presented radiodermatitis at 3 months (G1: 26%, G2: 6%) 
and only one patient presented radiodermatitis G1 at 6 
months. Toxicity score correlation to CTV volume, treatment 
depth, BED prescribed dose, D1cc, D0.5cc and D0,1cc had no 
statistical significance (p>0.05). Treated area was found to 
be predictive of radiodermatitis persistence at 3 months 
after treatment (p=0.036). Lesions located in the legs showed 
longer recovery time from radiodermatitis than other 
locations (4 months vs 1.8 months average). 
 
Conclusion: The use of these VHVAS moulds was well-
tolerated by all patients. Our treatments yield similar results 
to other groups with similar treatment schemes in terms of 
acute toxicity. We can conclude that VHVAS custom made 
molds have a good safety profile. 
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Purpose or Objective: Formerly in the 2D Low-Dose Rate 
(LDR) era no information about Dose-Volume Histogram (DVH) 
parameters of organs at risk (OARs) was available in 
brachytherapy plans. To enable research on late dose effects 
for children treated with Pulsed-Dose Rate (PDR), 3D dose 
distributions and DVH parameters are required. In this study 
a method was developed to enable calculation of DVH 
parameters. 
 
Material and Methods: Before 2001 pediatric head and neck 
(H&N) patients received LDR brachytherapy as a part of their 
treatment. Of 16 LDR plans (1989-2001) only hard-copy CT 
data, orthogonal x-ray images of the implant and 
documented 2D dose information were available. The 
documented 2D dose information consisted of source 
strength, catheter numbering, catheter loading, and 
treatment time. The hard-copy CT data was digitized, 
transferred to DICOM format and imported in Oncentra 
Brachy (Elekta, v4.3). The visible OARs were delineated and 
used catheters were reconstructed. The Ir192-LDR line 
sources from the original 2D plans were simulated by loading 
the reconstructed catheters with Ir192-PDR source tracks of 
the same length as the LDR sources, with a step size of 
2.5mm. Simulation of a line source dosimetry was necessary 
because the planning system did not support LDR planning. 
All PDR source dwell times were made equal, but scaled to 
the documented 2D dose distribution to obtain the 3D dose 
distribution at time of treatment. Scaling was performed at a 
2D LDR isodose level below 30% of the prescribed dose in a 
plane where the documented 2D dose distribution and 
transformed 3D dose distribution geometrically match. 
Scaling below 30% is done to avoid effects due to the non-
uniform isodose distribution very close to a stepping PDR 
source. To check the reliability of the method the Total 
Reference Air Kerma (TRAK) for both 2D LDR and 3D PDR 
plans were determined and compared. The difference was 
tested with the Wilcoxon Signed Rank Test for paired 
variables. To illustrate the applicability of the method the 
maximum dose, defined as the D0.1cm3, on e.g. chiasm was 
determined. 
 
Results: Of 16 LDR plans 2D data were transformed into 3D 
dose distributions. OARs and DVH parameters of chiasm were 
determined. The mean 2D TRAK was 0.95cGy/1m (IQR 0.89). 
The mean 3D TRAK was 0.89cGy/1m (IQR 0.74). The mean 
difference of 2D TRAK and 3D TRAK was statistically not-
significantly different from 0 (P=0.45). For 7 patients the CT 
data incorporated the chiasm area. The mean chiasm 
maximum dose was 233.6cGy (range 4.6-399.2) using the 
described method. 
 
Conclusion: With the described method it was possible to 
transform 2D LDR brachytherapy plans into a 3D dose 
distribution. This method shows the possibility to use 
information from 2D LDR brachytherapy plans in scientific 
studies in which 3D dose information is needed. 
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Purpose or Objective: To evaluate outcomes and toxicities 
after high dose-rate (HDR) endoluminal brachytherapy for the 
treatment of esophageal cancer patients. 
 
Material and Methods: We analyzed the patient records of 36 
patients treated with high dose-rate endoluminal 
brachytherapy for histologically confirmed esophageal 
cancer. Brachytherapy was either applied as a boost 
treatment for definitive radiotherapy and radio-
chemotherapy regimens or as a salvage treatment for 
recurrent tumors. Single radiation doses between 4 and 6 Gy 
were delivered to the endoscopically visible tumor including 
2 cm margins in 2 to 4 sessions. Recurrence-free and overall 
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survival as well as acute and late toxicities were 
retrospectively analyzed. 
 
Results: Brachytherapy was performed as initially planned in 
all but one patient. 18 patients had a complete endoscopic 
response at the first follow-up examination. Loco-regional 
recurrence was observed in 24 patients after a median time 
of 3 months; 1- and 2-year recurrence-free survival rates 
were 51% and 51% for the patients treated for primary tumors 
and 11% and 6% for patients treated for tumor recurrence, 
respectively. Median overall survival was 18 months; 
estimated overall survival rates at 1, 2 and 3 years were 63%, 
50% and 30% after primary brachytherapy, and 60&, 25% and 
6% after treatment for recurrent cancers. Adenocarcinoma 
histology, non-complete remission after treatment and 
treatment for recurrent cancers were associated with 
significantly reduce prognosis. Mild to moderate dysphagia 
was the most common side effect in 17 patients; 8 patients 
suffered from loco-regional grade 3 toxicities, and no grade 4 
or 5 toxicities were observed. 
 
Conclusion: Endoluminal brachytherapy during the course of 
esophageal cancer treatment can be safely applied and 
results in good functional outcomes regarding dysphagia with 
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Purpose or Objective: To describe the technique used in our 
department for treatment of cutaneous tumors with HDR 
plesiotherapy using custom moulds and to analyze long term 
results.  
 
Material and Methods: 
Custom made mould fabrication:  
We used this aplicator in irregular areas of skin.  
The treatment sequence is:  
- Creation of the mould with thermoplastic material with a 
thickness of 5 mm.  
- Parallel placement of transfer guide tubes with 1 cm of 
separation.  
- CT simulation and definition of the volume treat. The 
volume has to be delimited 5 mm in deep.  
- Dosimetry.  
- Treatment of the patient.  
We used 3 different schedules:  
- 54 Gy in 18 fractions  
- 66 Gy in 33 fractions  
- 40 Gy in 10 fractions 
 
Results: From September 2008 until September 2015 53 
patients had been treated with this technique.  
The average age was 77 years (63-91), the histology was 
squamous in 6 cases, basocellular in 46 cases, melanoma in 
situ in 1 case.  
The mean dose was 54.8 Gy (40-66). The treatment was 
adjuvant after surgery in 41,5% of the patients. 
After a mean time of follow up was 34,1 months there were 2 
local relapses (3.77%) in the treatment location. No deaths 
related to disease were observed. 
 
Conclusion: Treatment with HDR plesiotherapy using custom 
moulds is a technique used to treat small lesions and/or 
irregular surface locations. Planning with CT scan allows to 
know the dose in organs at risk using dose-volume histogram. 
This treatment offers a high local control of the disease and 
can be used alone or as adjuvant treatment after surgery in 
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Purpose or Objective: Previous literatures showed prior liver 
external beam radiotherapy (EBRT) may increase liver 
toxicity after yttrium-90 (90Y) selective internal radiation 
therapy (SIRT). In contrast, the safety of EBRT followed by 
SIRT is unclear. We investigated the safety and efficacy of 
EBRT followed by SIRT in hepatocellular carcinoma (HCC) 
patients. 
 
Material and Methods: Between October 2011 and May 2015, 
a total of 11 HCC patients who had treated with SIRT 
followed by liver salvage EBRT were enrolled. The SIRT 3-
dimensional absorbed dose distribution of each patient was 
retrospectively calculated on a voxel base, using post-
treatment bremsstrahlung SPECT/CT images. The physical 
dose and biological effective dose (BED) of SIRT and EBRT 
were generated and summed for evaluation. The dose-
volume histograms (DVHs) of the EBRT, SIRT, and combined 
therapy were analyzed. Liver-related toxicities were 
collected by chart-review and classified as Common 
Terminology Criteria for Adverse Events version 4. 
 
Results: The median time interval of SIRT and EBRT was 95 
days (IQR: 66.5-129.5 days). Eight patients (73%) had 
undergone EBRT for portal vein thrombosis (PVT) and 6 
patients (55%) for residual hepatic tumor. The mean SIRT, 
EBRT, and combined therapy normal liver BED were 
52.1±21.0 Gy, 17.9±6.1 Gy, and 69.5±15.0 Gy, respectively. 
The summed DVH of each patient is depicted in Figure 1. The 
image study three months post-irradiation showed primary 
disease PR in 4 patients (67 %) of patients and thrombosis 
improved in 6 patients (75%) after EBRT. Two patients had no 
evidence of disease after combined therapy. The median 
survival was 359.9 days. Total 3 patient (27 %) had developed 
≧grade 2 liver toxicities. Patient who experienced 
hepatotoxicity had higher summed BED (107.0±7.3 Gy vs 
58.9±13.5 Gy; P = 0.02). The univariate analysis of summed 
DVH showed that the fraction of normal liver exposed to 
more than 70 Gy (V70) was the strongest predictor of 
hepatotoxicity (9.4±7.2% vs 29.9±4.4%; P=0.007), as 
presented in Table 1.  




Table 1. Dosimetric parameter univariate analysis 
